Cardiac fibrosis inhibitor CTPR390 prevents structural and morphological changes in human engineered cardiac connective tissue
Summary
Cardiac fibrosis is a key characteristic of heart failure. CTPR390, an experimental anti-fibrotic inhibitor targeting Hsp90, has shown success in animal models, but remains unexplored in human cardiac models. This study evaluated an engineered cardiac connective tissue (ECCT) model, focusing on changes in the extracellular matrix and fibroblasts. Results showed that CTPR390 prevented architectural changes in TGFβ1-activated ECCT, preserving tissue perimeter, collagen fibers alignment while reducing structured areas and degree of collagen structuration. CTPR390 treatment reduced cell area of fibroblasts under tension, without changes in the internal rounded cells devoid of tension. Fibroblast recruitment to tension areas was diminished, showing biomechanical behavior similar to control ECCT. This treatment also lowered the gene and protein expression of key pro-fibrotic markers. Here, advanced biotechnology was employed to detect the detailed structure of tissue fibrosis reduction after administering CTPR390, representing a significant advancement toward clinical application for cardiac fibrosis treatment. © 2025 The Author(s).
| Authors | Maestro D, Palanca A, Soto H, Llarena I, DeGrave AN, Guedes G, Henrique de Oliveira G, Coelho Conceição AL, Mieites V, Icardo JM, Sanchez-Cano C, Conde OM, Lutz S, Cortajarena AL, Villar AV |
|---|---|
| Journal | iScience |
| Publication Date | 2025 Aug 15;28(8):113013 |
| PubMed | 40686602 |
| PubMed Central | PMC12275948 |
| DOI | 10.1016/j.isci.2025.113013 |